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New Findings
 What is the topic of this review?
In this review, we discuss recent findings that provide a novel insight into the mechanisms
that link glial cell functionwith the pathogenesis of cardiovascular disease, including systemic
arterial hypertension and chronic heart failure.
 What advances does it highlight?
We discuss how glial cells may influence central presympathetic circuits, leading to
maladaptive and detrimental increases in sympathetic activity and contributing to the
development and progression of cardiovascular disease.
Increased activity of the sympathetic nervous system is associated with the development
of cardiovascular disease and may contribute to its progression. Vasomotor and cardiac
sympathetic activities are generatedby theneuronal circuits located in thehypothalamus and the
brainstem. These neuronal networks receive multiple inputs from the periphery and other parts
of theCNSand, at a local level,maybe influencedby theirnon-neuronalneighbours, inparticular
glial cells. In this review, we discuss recent experimental evidence suggesting that astrocytes
and microglial cells are able to modulate the activity of sympathoexcitatory neural networks
in disparate physiological and pathophysiological conditions. We focus on the chemosensory
properties of astrocytes residing in the rostral ventrolateral medulla oblongata and discuss
signalling mechanisms leading to glial activation during brain hypoxia and inflammation.
Alterations in these mechanisms may lead to heightened activity of sympathoexcitatory CNS
circuits and contribute tomaladaptive and detrimental increases in sympathetic tone associated
with systemic arterial hypertension and chronic heart failure.
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Introduction
Cardiovascular disease remains themost commoncause of
death in Western societies, although the relative mortality
attributable to it has decreased significantly in the last
decade (Go et al. 2013). Hypertension is an important
risk factor for the development of cardiovascular disease,
and recent statistics from the American Heart Association
suggest that approximately one-third of adults in the
USA are hypertensive (Go et al. 2013). Despite significant
progress in the prevention, diagnosis and treatment of
hypertension, only half of patients show satisfactory
response to treatment (Go et al. 2013). Inadequate
adherence to antihypertensive medication is an important
factor that affects diseasemanagement.However, relatively
poor efficacy of the existing antihypertensive therapies
might also be due to the fact that conventional treatments
target the peripheral mechanisms that maintain high
systemic blood pressure, whereas primary CNS factors are
responsible for the development and progression of the
disease and remain untreated.
The pathophysiology of cardiovascular disease is
complex, multifactorial and, in many respects, poorly
understood. In this review, we focus on essential hyper-
tension and chronic heart failure, which are conditions
known to be associated with significant changes in
the central nervous mechanisms of cardiovascular
control. Indeed, recent advances in autonomic nervous
system monitoring techniques in humans (including
microneurography, measurement of noradrenaline
spillover, assessmentofheart rate variability andbaroreflex
sensitivity) have shown that increased activity of the
sympathetic nervous system is intimately linked with
the development and progression of both essential
hypertension and chronic heart failure (Hasking et al.
1986; Leimbach et al. 1986; Esler et al. 1989; Kaye et al.
1995; Grassi et al. 1998; La Rovere et al. 1998, 2003; Esler
& Kaye, 2000; Esler et al. 2001). In these conditions,
complex interactions between behavioural, nutritional
and humoral factors, altered activity of cardiovascular
afferents (baro- and chemoreceptors) and modifications
in the central nervous control mechanisms all lead to
increased sympathetic efferent activity (Vallbo et al. 1979;
Trzebski et al. 1982; Grassi et al. 1988, 2002; Mark, 1990;
van de Borne et al. 1997; Schultz & Sun, 2000; Carlyle et al.
2002; Schultz et al. 2007; Grassi, 2009; Sin´ski et al. 2012;
May et al. 2013). In hypertension, enhanced sympathetic
tone, along with humoral and vascular factors, is believed
to play a significant role in the development and
maintenance of high arterial blood pressure. In heart
failure, sympathetic drive increases in parallel with the
progression of the disease as a compensatory measure
aimed to preserve ventricular contractile function.
However, in the long-term, sustained elevation of
sympathetic tone becomes maladaptive and detrimental,
leading to morphological and functional changes in the
peripheral vasculature and the myocardium, including
hypertrophy and proliferation of smooth muscle cells
(Bevan, 1984), increased arterial stiffness (Boutouyrie
et al. 1994), endothelial dysfunction (Pettersson et al.
1990), atherosclerosis (Kaplan et al. 1987), increased
left ventricular mass (Simpson, 1983) and increased
arrhythmogenesis (Lown&Verrier, 1976). Understanding
theCNSmechanisms that underlie the increases in activity
of the sympathetic nervous system is, therefore, important
for the development of novel therapeutic strategies to
treat hypertension and heart failure, and may ultimately
help to reduce the clinical, social and economic burden of
cardiovascular disease.
Vasomotor and cardiac neural activities of spinal
sympathetic preganglionic neurones depend on tonic
descending excitatory drive generated by sympatho-
excitatory (presympathetic) neuronal circuits residing
in the brainstem and the hypothalamus (Dampney,
1994; Spyer, 1994; Guyenet, 2000; Dampney et al. 2003;
Madden & Sved, 2003). These circuits include the rostral
ventrolateral medulla (RVLM), rostral ventromedial and
mid-line medulla, the A5 cell group of the pons and
the hypothalamic paraventricular nucleus (PVN; Strack
et al. 1989; Dampney et al. 2003; Madden & Sved,
2003; Kanbar et al. 2011; Marina et al. 2011). Although
RVLM neurones responsible for sympathetic control of
cardiovascular activities have been studied extensively
(see Guyenet, 2013), little or no attention has been
paid to their non-neuronal neighbours, astrocytes and
microglia. Here, we review recent evidence suggesting that
changes in astroglial andmicroglial activities contribute to
modifications in central nervous autonomic control and,
therefore, may play an important role in the development
and progression of cardiovascular disease associated with
increased activity of the sympathetic nervous system
(Marina, 2013; Marina, 2015; Rana et al. 2010; Shi et al.
2010; Zubcevic et al. 2011).
Glial cells
Astrocytes are the most abundant CNS glial cells and
occupy non-overlapping territories that define their
functional domains (Halassa et al. 2007). Astrocytes were
traditionally considered as a rather passive CNS cellular
component that assisted neuronal circuits to maintain
their function by providing nutritional and structural
support. However, significant evidence accumulated in
the last two decades suggests that astrocytes may play
an active role in the regulation of synaptic strength
and information processing (Halassa et al. 2009). In
pathological conditions, astrocytes respond to CNS injury
with significant changes in gene expression, morphology
and function. This process, called astrogliosis, might have
both beneficial and detrimental effects on tissue repair
C© 2016 The Authors. Experimental Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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and might potentially influence the activity of neuronal
networks (Sofroniew, 2015).
Microglial cells are resident immune cells in the CNS
involved in the detection of invading organisms and brain
injury. Microglial cells are less abundant than astrocytes,
making up 20% of all brain glial cells. In resting
conditions,microglial cells present a ramifiedmorphology
characterized by a small soma and extensive branched
and long processes, which might make direct contact
with neurones, astrocytes and cerebral vasculature. In
response to brain injury,microglial cells become activated,
undergo significant morphological changes and release
various substances that may exert either neuroprotective
or neurotoxic effects (Badoer, 2010).
Gliotransmission
Significant experimental evidence indicates that
communication between glial cells and CNS neurones
is bidirectional in nature. Astrocytes are capable of
controlling synaptic communication via complex
interactions with presynaptic and postsynaptic elements
(Perea et al. 2009). Astrocytes release (glio)transmitters in
response to activationofG-protein-coupled receptors and,
when activated, generate intracellular Ca2+ responses.
Several molecules identified as gliotransmitters can be
released by activated astrocytes, including ATP/adenosine,
D-serine, glutamate, GABA, L-lactate and possibly some
others (Volterra & Meldolesi, 2005; Holmstro¨m et al.
2013; Tang et al. 2014; Marina et al. 2015).
One well-documented astroglial signalling mechanism
involves the release of ATP. The ATP released by activated
astrocytes into the extracellular space acts on purinergic
(P2) metabotropic and ionotropic receptors expressed
by adjacent astrocytes, neurones and other glial cells
(Gourine et al. 2009). Ectonucleotidases break down ATP
to ADP, AMP and adenosine, which in turn can activate
a different group of G-protein-coupled adenosine (P1)
receptors (Burnstock, 2007).
Although release of (glio)transmitter(s) can be
triggered by many stimuli, the physiological significance
of gliotransmission has been debated. According to some
estimates, the amount of glutamate contained within
astroglial ‘vesicles’ is not sufficiently high to trigger
changes in the neuronal activity following its release
(Bramham et al. 1990). Indeed, the functional significance
of gliotransmission is difficult to demonstrate because
the approaches commonly used to stimulate astrocytes
and to interfere with gliotransmitter release are generally
non-specific (Hamilton & Attwell, 2010). When genetic
methods of selective activation and blockade of astrocytic
Gq G-protein-coupled receptor-mediated Ca2+ signalling
mechanisms were applied in animal models, neuronal
excitatory synaptic transmission in the hippocampus, as
well as short- and long-term plasticity were found to
be unaffected (Fiacco et al. 2007; Agulhon et al. 2010).
This may be explained by the fact that mature astrocytes
do not express metabotropic glutamate receptor 5, thus
casting further doubt on the role of glutamate inmediating
communication between neurones and astrocytes (Sun
et al. 2013). These results emphasize the importance of
ATP-mediated signalling by astrocytes, which is further
supported by the recent studies demonstrating that ATP
release by brainstem astrocytes plays an important role in
the CNS mechanisms that maintain cardiovascular and
respiratory homeostasis.
Glial cells and central chemosensitivity
There is significant evidence that astrocytes are involved
in central chemosensory mechanisms that maintain
cardiorespiratory homeostasis (Gourine et al. 2010;
Marina et al. 2013). In mammals, these mechanisms
are vital in producing adaptive changes in breathing in
response to changes in PCO2/pH and PO2 in the arterial
blood and brain parenchyma. Systemic hypercapnia,
leading to decreases in blood and brain pH, is associated
with a rapid release of ATP within the chemosensory areas
of the brainstem (Gourine et al. 2005b). Interestingly,
these chemosensitive areas are located immediately
underneath and in close proximity to the populations
of RVLM presympathetic and ventral respiratory column
neurones, which generate co-ordinated sympathetic and
respiratory rhythms (Gourine et al. 2005a,b; 2010).
Hypercapnia-induced ATP release is independent of the
peripheral chemoreceptor inputs (Gourine et al. 2005b)
and occurs within the appropriate time frame and in
sufficient quantities to be responsible for the subsequent
increases in breathing. Consistent with this, blockade
of ATP receptors at the sites of release reduces the
CO2-induced increase in breathing, whereas application
of ATP evokes an increase in the respiratory activity,
mimicking the effect of CO2 (Gourine et al. 2005b).
Recent studies have also provided evidence that brain-
stem astrocytes are exquisitely sensitive to changes in
pH within the physiological range and may represent
the main source of ATP released in the brainstem
during hypercapnia (Gourine et al. 2010). In contrast to
cortical astrocytes, ventral brainstem astrocytes respond
to acidification with elevations in intracellular Ca2+ and
an increased rate of exocytosis of ATP-containing vesicular
compartments (Kasymov et al. 2013). This suggests that
ventral brainstem astrocytes are functionally specialized
for monitoring physiological increases in PCO2/[H
+] and
responding to these increases with the release of ATP
(Kasymov et al. 2013). ATP propagates Ca2+ excitation
among neighbouring astrocytes, activates neurones of the
ventral respiratory column and, thus, contributes to the
adaptive increases in the respiratory activity (Gourine
et al. 2010).
C© 2016 The Authors. Experimental Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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Astrocytes also appear to be sensitive to physiological
changes in brain O2 content. They respond to decreases
in PO2 a few millimetres of mercury below normal
brain oxygenation with robust increases in intracellular
[Ca2+]. Hypoxia is detected in mitochondria, where
O2 is consumed (Angelova et al. 2015). Decreases
in PO2 inhibit mitochondrial respiration, leading to
mitochondrial depolarization, production of free radicals,
lipid peroxidation, activation of phospholipase C and
Inositol triphosphate (IP3) receptors, resulting in
recruitment of Ca2+ from the intracellular stores and
vesicular release of ATP (Angelova et al. 2015; Fig. 1).
This hypoxia-induced astroglial ATP release has been
demonstrated to maintain enhanced respiratory activity
even in the absence of oxygen sensing by the peripheral
chemoreceptors (Angelova et al. 2015).
Role of brainstem glia in the pathogenesis
of cardiovascular disease
New evidence suggests that glial dysfunction may
be responsible for the pathogenesis of certain
neurodevelopmental disorders previously attributed to
primary neuronal abnormalities. For example, recent
studies demonstrated that altered astroglial andmicroglial
functions contribute to the pathogenesis of Rett syndrome
(Lioy et al. 2011; Derecki et al. 2012; Okabe et al.
2012), a prototypical neurological disorder associated
with mutations of the methyl-CpG-binding protein 2
(MECP2) gene, which is manifested by neurological,
respiratory and autonomic deficiencies. In this section,
we discuss putative mechanisms that link altered glial
cell activity with maladaptive increases in excitability of
CNS presympathetic circuits, which may contribute to
the detrimental sympathetic activation in cardiovascular
disease.
Hypoxia. The (patho)physiological conditions associated
with activation of RVLM astrocytes and downstream
responses of presympathetic circuits are still unclear,
although this mechanism may become significant in
conditions of central hypoxia,which is a powerful stimulus
for the release of ATP and lactate in the RVLM (Gourine
et al. 2005b; Karagiannis et al. 2015). ATP was previously
shown to be released from within the RVLM in response
to hypoxia (10% inspiredO2, 5min). This release was only
slightly attenuated in animals with bilateral sectioning
of vagi, aortic and carotid sinus nerves, suggesting that
most of the hypoxia-induced ATP release originates
from astrocytes. It was also found that the amount of
hypoxia-induced ATP released from the ventral medullary
structures is similar to that released in response to CO2
(Gourine et al. 2005a). Activation of ATP receptors in the
RVLM bymicroinjections of ATP or stable ATP analogues
has been shown to activate bulbospinal presympathetic
connexin-mediated
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Figure 1. Neuroglial interactions in the rostral ventrolateralmedulla oblongata hypothesized to underlie
pathological increases in sympathetic nerve activity in chronic heart failure and essential hypertension
Tissue hypoxia and increased concentration of CO2/H+ is detected by astrocytes, leading to the release of
ATP and lactate, which in turn increase the excitability of bulbospinal sympathoexcitatory (C1) neurones.
Abbreviations: Cx, connexin; and IML, intermediolateral cell column.
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neurones, leading tomarked increases in the arterial blood
pressure, heart rate and renal sympathetic nerve activity
(Sun et al. 1992;Horiuchi et al. 1999; Ralevic, 2000). These
data are consistent with the hypothesis that increases in
the level of ‘ambient’ ATP within the RVLM as a result of
hypercapnia and/or hypoxia-induced activation of brain-
stem astrocytes may contribute to the increases in central
sympathetic drive (Fig. 1).
Factors that trigger and maintain astrocytic activation
during the development and progression of heart failure
remain unknown. Both obstructive sleep apnoea and
central sleep apnoea are common clinical features in
heart failure patients (Bradley & Floras, 2003a,b). These
conditions are associated with recurrent episodes of
systemic hypoxia and hyper/hypocapnia. Brain tissue
oxygen content in many heart failure patients was found
to be significantly decreased despite nearly normal oxygen
levels measured in the arterial blood (Rifai et al. 2012).
Therefore, a hypoxic environment is likely to result in
higher extracellular concentrations of ATP within the
brainstem and this, as discussed above, may increase
the activity of presympathetic neurones and result in
higher sympathetic tone (Fig. 1). Indeed, sympathetic tone
appears to be significantly higher in heart failure patients
with sleep apnoea in comparison to heart failure patients
with normal breathing patterns (Naughton et al. 1995;
Mansfield et al. 2003).
Similar mechanisms may also underlie sympatho-
excitation associated with the development of systemic
arterial hypertension (Marina et al. 2015). Earlier studies
demonstrated that basilar artery diameter in animal
models of hypertension (spontaneously hypertensive
rats, SHRs) is reduced, resulting in increased vascular
resistance (Cates et al. 2011, 2012). Structural changes
of brain vasculature are unlikely to be a consequence of
hypertension because they are evident in prehypertensive
animals (Cates et al. 2011, 2012). It was reported
recently that tissue PO2 in the RVLM of the SHR is
lower than in normotensive counterparts (despite normal
levels of arterial PO2), suggesting that in the SHR the
sympathoexcitatory networks are exposed to a hypoxic
environment (Marina et al. 2015). Thus, in neurogenic
hypertension, the Cushing mechanism is hypothesized
to maintain brain perfusion by increasing systemic
arterial blood pressure. Increased sympathetic activity and
systemic hypertension can be viewed as a compensatory
mechanism activated to preserve oxygen delivery and
maintain brain oxygenation at the expense of systemic
hypertension (Rodbard & Stone, 1955; Cates et al. 2011,
2012).
Brain hypoxia is known to trigger robust activation of
the RVLM presympathetic neurones (Sun & Reis, 1994).
There is evidence suggesting that the sensitivity of the
RVLM presympathetic neurones to decreases in PO2 is
mostly indirect and mediated by prior release and actions
of both ATP and lactate, released by astrocytes (Fig. 2;
Marina et al. 2015).
In a similar manner to ATP, lactate, which is also
released by activated astrocytes (Tang et al. 2014),
produces strong excitation of C1 neurons in vitro and
increases in sympathetic nerve activity and the arterial
blood pressure when applied on the brainstem surface
(Marina et al. 2015). Together, these lines of evidence
suggest that both heart failure and hypertension are
associated with a decrease in brain parenchymal oxygen
content, accumulation of ATP and lactate within the
presympathetic brainstem areas, leading to increased
activity of sympathoexcitatory neurons and concomitant
sustained elevation of sympathetic drive (Fig. 1). It
remains to be determined whether in the human
brain, tissue extracellular ATP and lactate concentrations
are correlated with the severity of the sympathetically
mediated cardiovascular diseases.
Increased purinergic (glio)transmission in the brainstem.
Activated brainstem astrocytes signal to bulbospinal
sympathoexcitatory neurones. It was shown that
optogenetic stimulation of RVLM astrocytes (transduced
with viral vectors to express light-sensitive channels,
e.g. channelrhodopsin 2) excites presympathetic RVLM
neurones belonging to the C1 catecholaminergic
group (Marina et al. 2013). These responses were
attenuated in the presence of an ATP-degrading
enzyme, apyrase, demonstrating a key role for
ATP in mediating communication between activated
astrocytes and presympathetic neurones (Marina et al.
2013). Furthermore, in vivo experiments conducted in
anaesthetized and artificially ventilated rats showed that
optogenetic activation of channelrhodopsin 2-expressing
astrocytes within the RVLM produces robust elevations
in renal sympathetic nerve activity, heart rate and arterial
blood pressure (Marina et al. 2013; Fig. 3). Thus, selective
recruitment of [Ca2+]i in RVLM astrocytes using an
optogenetic approach is sufficient to trigger activation of
sympathoexcitatory CNS circuits.
It was also shown in a rat model of heart failure
that ATP-mediated purinergic signalling in the RVLM
plays an important role in sympathoexcitation, which is
associated with, and may contribute to, the progression
of left ventricular remodelling after a myocardial
infarction. Given that specific ‘inhibition’ of astroglial
activity/function is difficult to achieve (and it is not
always easy to choose which of their functions has to
be targeted), we reasoned that the role of astrocytes
in the control of sympathetic activity in pathological
conditions could be investigated by using experimental
tools that prevent communication between these cells.
To interfere with ATP-mediated signalling, a lentiviral
vector was developed in order to drive expression
of a potent ectonucleotidase, transmembrane prostatic
C© 2016 The Authors. Experimental Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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acid phosphatase (TMPAP), the effect of which is to
facilitate rapid breakdown of extracellular as well as
vesicular ATP (Wells et al. 2015). The TMPAP was
tagged with green fluorescent protein, anchored to
the plasma membrane and had a catalytic domain
facing the extracellular space. Bilateral overexpression of
TMPAPwithin theRVLMpresympathetic circuits reduced
sympathetic activity in developing heart failure (evident
from a lower plasma concentration of noradrenaline) and
slowed the progression of left ventricular remodelling and
dysfunction (Marina et al. 2013). These data provided
the first experimental evidence suggesting that altered
glial activity leading to a higher level of ‘ambient’ ATP
in the brainstem might be responsible for the increases
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and null (control) biosensors placed on the ventral medullary surface. The difference in current between
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imaging using TN-XXL).D, summary data illustrating the effects ofMRS2179 andDAB on hypoxia-induced
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in sympathetic tone and, by doing so, contribute to
progression of heart failure (Fig 1).
Recent studies have demonstrated that ATP-mediated
purinergic signalling in the RVLM may also play a role in
the development of neurogenic hypertension. Facilitated
breakdown of ATP with targeted overexpression of virally
driven TMPAP in the RVLM resulted in a significant
reduction of the systemic arterial blood pressure in the
SHR (Marina et al. 2015). There is also recent evidence
to suggest that ATP-mediated signalling may contribute
to alterations in the central nervous mechanisms of
autonomic control and development of hypertension in
a rat model of chronic intermittent hypoxia. Increases in
sympathetic nerve discharge evoked by microinjections
of ATP into the RVLM were found to be significantly
higher in rats exposed to chronic intermittent hypoxia
(Zoccal et al. 2011). Chronic intermittent hypoxia was also
associated with a significant upregulation of ATP receptor
(P2X3 and P2X4 subunits in particular) expression in the
RVLM (Zoccal et al. 2011). It remains to be determined
whether increased ATP-mediated signalling in the RVLM
in a rat model of chronic intermittent hypoxia originates
from activation of astrocytes in response to recurrent
changes in the brainstem tissue PO2 (Angelova et al. 2015).
Microglial cell activation, astrogliosis and inflammation.
Subtle chronic inflammation is a hallmark feature in
the pathogenesis of chronic heart failure and essential
hypertension. Indeed, in an animal model of heart
failure, the expression of the pro-inflammatory cytokines
interleukin-1β (IL-1β) and tumour necrosis factor-α
(TNF-α) was found to be significantly increased in at least
one brain site that controls sympathetic outflow, namely
the hypothalamic paraventricular nucleus (Kang et al.
2008, 2009). Clear evidence ofmicroglial activationwithin
the PVN after myocardial infarction was also reported
(Rana et al. 2010).
Experimental models of hypertension (rats receiving
chronic infusion of angiotensin II) provided further
evidence of microglial activation and enhanced produc-
tion of pro-inflammatory cytokines in the presympathetic
regions of the brain (PVN in particular; Shi et al.
2010). Activated microglial cells and inflammatory
cytokines can evoke and amplify gliotransmitter release
by astrocytes (Cotrina et al. 2000; Bezzi et al. 2001;
Domercq et al. 2006; Pascual et al. 2012). Interestingly,
in the model of hypertension induced by angiotensin II
infusion, intracerebroventricular application of an anti-
inflammatory antibiotic, minocyclin, decreased the
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number of activated microglial cells and reduced the
expression of pro-inflammatory cytokines in the PVN.
Suppression of microglial activity and PVN inflammation
was associated with lower systemic arterial blood pressure,
attenuated ventricular hypertrophy and lower plasma
noradrenaline, all of which are indicative of a reduced
sympathetic activity (Shi et al. 2010).
Immunohistochemical studies have also revealed
microglial activation in the PVN of SHRs (Shi
et al. 2010; Zubcevic et al. 2011). Recent data
demonstrated that cultured hypothalamic microglial cells
are directly activated by prorenin, a component of
the renin–angiotensin system, resulting in induction of
pro-inflammatorymechanisms in these cells via activation
of nuclear factor-κB (Shi et al. 2014). It remains to be
determined whether heart failure and hypertension are
associated with similar changes in microglial function in
other CNS areas involved in cardiovascular control.
There is also significant evidence to suggest that in
pathological conditions, astrogliosis may lead to altered
gliotransmission, which may affect neuronal excitability
and result in neurotoxicity. Chronic astroglial activation
occurs in response to an increase in extracellular ATP
as well as in response to the actions of inflammatory
cytokines, including IL-1β and TNF-α (Bezzi et al. 2001;
Liu et al. 2011; Pascual et al. 2012), released locally by
activated microglia. For example, in acute hippocampal
slices, activated microglia release small amounts of ATP,
which triggers waves of Ca2+ excitation in astrocytic
networks (via stimulation of P2Y1 receptors), leading
to the release of glutamate and an increased frequency
of excitatory postsynaptic events in adjacent neurones
(Pascual et al. 2012). Furthermore, TNF-α released by
activated microglia induces further release of TNF-α
by local astrocytes. These interactions between activated
micro- and astroglia result in a significant production
of TNF-α, followed by a release of glutamate (Bezzi
et al. 2001). All these factors are capable of initiating
propagating waves of Ca2+ excitation within astroglial
networks andmodulating the excitability of local neuronal
circuits (Cotrina et al. 2000; Bezzi et al. 2001; Pascual
et al. 2012). Thus, in pathological conditions, the
activity of CNS neuronal networks may be affected by
altered gliotransmission initiated andmaintainedby tissue
hypoxia and by the actions of inflammatory cytokines
released by activated microglia.
There is morphological evidence of glial abnormalities
in the brains of hypertensive subjects (Tomassoni et al.
2004). In an attempt to ‘inhibit’ astrocytic activity in SHRs,
non-specific pharmacological agents, such as arundic acid,
have been used. Arundic acid suppresses synthesis of
S100B (Asano et al. 2005), a glia-specific Ca2+-binding
protein important for the expression of pro-inflammatory
cytokines and control of apoptosis (Marenholz et al. 2004).
Interestingly, treatmentof SHRswith arundic acid resulted
in a significant reduction in the arterial blood pressure and
prevented hypertension-related strokes (Higashino et al.
2009).
Previous studies have also revealed an association of
events that may link microvascular inflammation and
brain hypoxia with astroglial activation of presympathetic
networks. Experiments using RT-PCR showed increased
expression of a pro-inflammatory molecule, junctional
adhesion molecule-A (JAM-A), in the endothelial cells
of arterioles supplying the dorsal brainstem structures
of both young (pre-hypertensive) and adult SHRs (Waki
et al. 2007). Overexpression of JAM-A in the dorsal
medullary regions using viral vectors led to a significant
increase in systolic blood pressure in control (Wistar)
rats, and this was accompanied by leucocyte adhesion
to the brainstem microvasculature (Waki et al. 2007,
2008). Moreover, body-wide downregulation of JAM-A
using a specially formulated ‘vivo’ morpholino delayed
development of hypertension in the SHR (Xu et al. 2012).
There is also evidence that infiltration of monocytes in the
brain microvasculature triggers the synthesis of cytokines,
including monocyte chemoattractant protein-1, by
astrocytes (Andjelkovic et al. 2000). Therefore, leucocyte
adhesion to the brainstem microvasculature may result
in astroglial activation and upregulation of cytokine
expression (Waki et al. 2008). In addition, increased
leucocyte adhesion may produce partial blood flow
obstruction, resulting in increased vascular resistance,
reduced tissue perfusion and hypoxia (Paton & Waki,
2009). This may be sufficient to trigger astroglial
activation, inflammation and gliotransmitter (ATP)
release, leading to increased excitability of presympathetic
circuits and enhanced central sympathetic drive in
neurogenic hypertension.
Conclusion
The active role of glial cells in the central nervous
mechanisms that maintain cardiovascular homeostasis
in physiological and pathological conditions is a novel
concept, and the intimate details of neuroglial interactions
in the brainstem are only starting to be explored.
The experimental evidence reviewed here identifies two
potential mechanisms of how glial cells may impart
their activity on presympathetic CNS networks (both
hypothalamic and brainstem), leading tomaladaptive and
detrimental increases in sympathetic activity associated
with the development and progression of heart failure
and hypertension, as follows: (i) a decrease in cerebral O2
content that causes hypoxia-induced astroglial activation
(Fig. 1); and (ii) increased production of ATP (Fig. 1)
and pro-inflammatory cytokines by activated astrocytes
and microglia. Further advances in our understanding of
micro- and astroglial function will not only reveal the
role of these cells in modulating the activities of vital
C© 2016 The Authors. Experimental Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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presympathetic networks that control the heart and the
vasculature, butmay alsohelp to identify novel therapeutic
modalities for the treatment of cardiovascular disease.
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